![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
November 16, 2021
This phase II randomized controlled trial is evaluating the effect of adding hydroxychloroquine to treatment with dabrafenib and trametinib in patients with advanced BRAF mutant melanoma
March 31, 2021
This phase II study, led by Dr. Ahmad Tarhini, is testing neoadjuvant treatment with pembrolizumab alone versus pembrolizumab and an investigational drug called CMP-001
May 29, 2020
What we know about COVID-19; remembering Valerie Guild; spotlight on Indiana University's Melvin and Bren Simon Comprehensive Cancer Center
May 29, 2020
April 15, 2020
A single-arm phase II trial evaluating the effectiveness of treatment before surgery with encorafenib and binimetinib
April 15, 2020
